Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jul;8(1):49–51. doi: 10.1111/j.1365-2125.1979.tb05908.x

Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.

I B Davies, P S Sever, T Rosenthal
PMCID: PMC1429708  PMID: 399592

Abstract

1. The short term effects of hydrallazine, oxprenolol and oxprenolol plus hydrallazine were studied in five patients with essential hypertension. 2. The increase in pulse rate caused by hydrallazine was prevented by combined treatment with oxprenolol, which also lowered the high plasma noradrenaline levels, associated with the use of hydrallazine. 3. Plasma renin activity was higher in the supine and standing positions with hydrallazine than with oxprenolol alone and with the patients standing this high renin level was prevented by simultaneous treatment with oxprenolol. With the patients supine, combination of oxprenolol with hydrallazine resulted in a mean plasma renin activity which was less than half that with hydrallazine alone, although this difference was not statistically significant. 4. The combination of oxprenolol with hydrallazine did not lower the blood pressure further, but reduced the increased sympathetic activity which occurred with hydrallazine alone.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyd G. W., Fitz A. E., Adamson A. R., Peart W. S. Radioimmunoassay determination of plasma-renin activity. Lancet. 1969 Feb 1;1(7588):213–218. doi: 10.1016/s0140-6736(69)91237-9. [DOI] [PubMed] [Google Scholar]
  2. Davies R., Slater J. D. Is the adrenergic control of renin release dominant in man? Lancet. 1976 Sep 18;2(7986):594–596. doi: 10.1016/s0140-6736(76)90665-6. [DOI] [PubMed] [Google Scholar]
  3. FREIS E. D., ROSE J. C., HIGGINS T. F., FINNERTY F. A., Jr, KELLEY R. T., PARTENOPE E. A. The hemodynamic effects of hypotensive drugs in man. IV. 1-Hydrazinophthalazine. Circulation. 1953 Aug;8(2):199–204. doi: 10.1161/01.cir.8.2.199. [DOI] [PubMed] [Google Scholar]
  4. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  5. Hollifield J. W., Sherman K., Zwagg R. V., Shand D. G. Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. N Engl J Med. 1976 Jul 8;295(2):68–73. doi: 10.1056/NEJM197607082950203. [DOI] [PubMed] [Google Scholar]
  6. Pedersen E. B., Kornerup H. J. Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension. Acta Med Scand. 1975 Nov;198(5):379–383. doi: 10.1111/j.0954-6820.1975.tb19560.x. [DOI] [PubMed] [Google Scholar]
  7. ROWE G. G., HUSTON J. H., MAXWELL G. M., CROSLEY A. P., Jr, CRUMPTON C. W. Hemodynamic effects of 1-hydrazinophthalazine in patients with arterial hypertension. J Clin Invest. 1955 Jan;34(1):115–120. doi: 10.1172/JCI103053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Raine A. E., Chubb I. W. Long term beta-adrenergic blockade reduces tyrosine hydroxylase and dopamine beta-hydroxylase activities in sympathetic ganglia. Nature. 1977 May 19;267(5608):265–267. doi: 10.1038/267265a0. [DOI] [PubMed] [Google Scholar]
  9. Sannerstedt R., Stenberg J., Vedin A., Wilhelmsson C., Werkö L. Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment. Am J Cardiol. 1972 May;29(5):718–723. doi: 10.1016/0002-9149(72)90176-2. [DOI] [PubMed] [Google Scholar]
  10. Sever P. S., Osikowska B., Birch M., Tunbridge R. D. Plasma-noradrenaline in essential hypertension. Lancet. 1977 May 21;1(8021):1078–1081. doi: 10.1016/s0140-6736(77)92335-2. [DOI] [PubMed] [Google Scholar]
  11. Sever P. S., Peart W. S., Meade T. W., Davies I. B., Gordon D., Tunbridge R. D. Are racial differences in essential hypertension due to different pathogenetic mechanisms? Clin Sci Mol Med Suppl. 1978 Dec;4:383s–386s. doi: 10.1042/cs055383s. [DOI] [PubMed] [Google Scholar]
  12. Ueda H., Kaneko Y., Takeda T., Ikeda T., Yagi S. Observation on the mechanism of renin release by hydralazine in hypertensive patients. Circ Res. 1970 Oct;27(Suppl):201–206. [PubMed] [Google Scholar]
  13. Zacest R., Gilmore E., Koch-Weser J. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med. 1972 Mar 23;286(12):617–622. doi: 10.1056/NEJM197203232861201. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES